PDF herunterladen
CC BY-NC-ND 4.0 · Planta Med 2023; 89(02): 140-147
DOI: 10.1055/a-1821-8690
Biological and Pharmacological Activity
Original Papers

Food Interactions Observed in a Pharmacokinetic Investigation Comparing Two Marketed Cold Preparations (BNO1016 and ELOM-080) after Administration to Beagle Dogs – A Pilot Study

Jan Seibel
1   Bionorica SE, Dept. Clinical & Scientific Affairs R&D, Neumarkt i. d. O.Pf., Germany
,
Astrid Neumann
2   Bionorica Research GmbH, Dept. Bioanalytics, Innsbruck, Austria
,
Anne Müller
2   Bionorica Research GmbH, Dept. Bioanalytics, Innsbruck, Austria
,
Meinolf Wonnemann 
1   Bionorica SE, Dept. Clinical & Scientific Affairs R&D, Neumarkt i. d. O.Pf., Germany
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Sinupret extract (BNO 1016) and Gelomyrtol forte (ELOM-080) represent the two top-selling cold remedies in Germany nowadays. Whereas BNO 1016 is a typical immediate release coated tablet, ELOM-080 is an enteric-coated soft gelatin capsule. The latter formulation, however, is at risk of pharmacokinetic interactions affecting absorption, especially in cases of concomitant food intake. In the present pilot study, we investigated the risk of a possible food effect in three male beagle dogs. Single doses of BNO 1016 and ELOM-80 were administered under fasting and fed conditions. Blood was sampled up to 30 h post-administration and plasma concentrations of the characteristic ingredients of BNO 1016 as well as ELOM-080 analytes were determined. Pharmacokinetic parameters focusing on the rate and extent of absorption were derived. BNO 1016 analytes demonstrated a similar course in both the fasted and fed states. ELOM-080 analytes also showed a similar picture in the fasted state. However, lag times (time from administration to first quantifiable time point in plasma) of up to 2 h post-administration with corresponding time to reach maximum concentration (obtained directly from the measured concentration) values of 3 to 4 h were observed, reflecting a longer gastric residence time. In the fed state, ELOM-080 showed significant pharmacokinetic characteristics, suggesting a clear food effect. A major observation was a double peak phenomenon that could be observed in two of three dogs. Furthermore, lag times of some analytes, up to 3 – 4 h, and corresponding time to reach maximum concentration values, up to 6 – 8 h, occurred. In contrast to BNO 1016, these findings suggest that, as with other enteric-coated formulations, there may also be a significant risk for food effects with ELOM-080 in humans.

Key words

enteric-coated drug formulation - food effect - beagle dogs - Sinupret - Gelomyrtol


Publikationsverlauf

Eingereicht: 03. Dezember 2021

Angenommen nach Revision: 14. März 2022

Artikel online veröffentlicht:
06. Mai 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mäder K. Innovative Arzneiformen: Ein Lehrbuch für Studium und Praxis [Innovative Dosage Forms: A Textbook for Study and Practice]. 1st edition. Stuttgart: Wissenschaftliche Verlagsgesellschaft Stuttgart; 2009
    CrossrefGoogle Scholar
  • 2 Uhl P. Schnell oder langsam, wie sich die Freisetzung von Arzneimitteln modifizieren lässt [Fast or slow, how to modify the release of drugs]. DAZ 2019; 28: 44
    PubMedGoogle Scholar
  • 3 Bayrischer Apothekerverband. Marktdaten Selbstmedikation: Gesamtjahr 2020 [Self-medication Market Data: Full Year 2020]. OTC Manager 2021; 3: 8-33
    PubMedGoogle Scholar
  • 4 G. Pohl-Boskamp GmbH & Co. KG. Summary of product characteristics: Gelomyrtol forte. Approval No.: 6096046.00.00, Feb 2018. Accessed February 17, 2022 at: https://www.fachinfo.de/suche/fi/007773
    PubMedGoogle Scholar
  • 5 Han D, Wang N, Zhang L. The effect of myrtol standardized on human nasal ciliary beat frequency and mucociliary transport time. Am J Rhinol Allergy 2009; 23: 610-614
    CrossrefPubMedGoogle Scholar
  • 6 Dorow P, Weiss T, Felix R, Schmutzler H. Effect of a secretolytic and a combination of pinene, limonene and cineole on mucociliary clearance in patients with chronic obstructive pulmonary disease. Arzneimittelforsch 1987; 37: 1378-1381
    PubMedGoogle Scholar
  • 7 Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie 1995; 74: 733-737
    PubMedGoogle Scholar
  • 8 Zhang S, Skinner D, Hicks SB, Bevensee MO, Sorscher EJ, Lazrak A, Matalon S, McNicholas CM, Woodworth BA. Sinupret activates CFTR and TMEM16A-dependent transepithelial chloride transport and improves indicators of mucociliary clearance. PLoS One 2014; 9: e104090
    CrossrefPubMedGoogle Scholar
  • 9 Kreindler JL, Chen B, Kreitman Y, Kofonow J, Adams KM, Cohen NA. The novel dry extract BNO 1011 stimulates chloride transport and ciliary beat frequency in human respiratory epithelial cultures. Am J Rhinol Allergy 2012; 26: 439-443
    CrossrefPubMedGoogle Scholar
  • 10 Virgin F, Zhang S, Schuster D, Azbell C, Fortenberry J, Sorscher EJ, Woodworth BA. The bioflavonoid compound, Sinupret, stimulates transepithelial chloride transport in vitro and in vivo . Laryngoscope 2010; 120: 1051-1056
    CrossrefPubMedGoogle Scholar
  • 11 Bionorica SE. Summary of product characteristics: Sinupret extract. Approval No.: 84060.00.00, Jan 2018. Accessed February 17, 2022 at: https://www.fachinfo.de/suche/fi/014213
    PubMedGoogle Scholar
  • 12 Rossi A, Dehm F, Kiesselbach C, Haunschild J, Sautebin L, Werz O. The novel Sinupret dry extract exhibits anti-inflammatory effectiveness in vivo . Fitoterapia 2012; 83: 715-720
    CrossrefPubMedGoogle Scholar
  • 13 Karim A, Burns T, Wearly L, Streicher J, Palmer M. Food-induced changes in theophylline absorption. from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther 1985; 38: 77-83
    CrossrefPubMedGoogle Scholar
  • 14 Karim A, Burns T, Janky D, Hurwitz A. Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther 1985; 38: 642-647
    CrossrefPubMedGoogle Scholar
  • 15 Waldman SA, Morganroth J. Effect of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-169
    CrossrefPubMedGoogle Scholar
  • 16 Blume HH, Schug BS, Potthast H. Influence of food on the bioavailability of controlled/modified release products. In: Kuhlmann J, Weihrauch TR. eds. Clinical pharmacology 12, food–drug interactions. München, Bern, Wien, New York: Zuckschwerdt; 1996: 25-32
    Google Scholar
  • 17 Szurszewski JH. A migrating electric complex of the canine small intestine. Am J Physiol 1969; 217: 1757-1763
    CrossrefPubMedGoogle Scholar
  • 18 Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke HP, Kubbinga M, Lindahl A, Lukacova V, Münster U, Neuhoff S, Nguyen MA, Peer Av. Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernäs H, Langguth P. In vivo methods for drug absorption – comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci 2014; 57: 99-151
    CrossrefPubMedGoogle Scholar
  • 19 Lentz KA. Current methods for predicting human food effect. AAPS J 2008; 10: 282-288
    CrossrefPubMedGoogle Scholar
  • 20 Ewe K, Press AG, Bollen S, Schuhn I. Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector. Digest Dis Sci 1991; 36: 146-152
    CrossrefPubMedGoogle Scholar
  • 21 Davis SS, Hardy JG, Fara JW. The transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-892
    CrossrefPubMedGoogle Scholar
  • 22 Hendeles L, Weinberger M, Milavetz G, Hill 3rd M, Vaughan L. Food-induced “dose-dumping” from a once-a-day theophylline product as a cause of theophylline toxicity. Chest 1985; 87: 758-765
    CrossrefPubMedGoogle Scholar
  • 23 European Medicines Agency (EMA):. EMEA/CHMP/EWP/280/96 Rev1. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. November 2014. Accessed February 17, 2022 at: https://www.ema.europa.eu/en/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms
    PubMedGoogle Scholar
  • 24 Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. J Clin Pharmacol 2002; 53: 582-588
    CrossrefPubMedGoogle Scholar
  • 25 Aoyagi N, Ogata H, Kaniwa N, Uchiyama M, Yasuda Y, Tanioka Y. Gastric emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. J Pharm Sci 1992; 81: 1170-1174
    CrossrefPubMedGoogle Scholar
  • 26 Ramkumar D, Schulze KS. The pylorus. Neurogastroenterol Motil 2005; 17: 22-30
    CrossrefPubMedGoogle Scholar
  • 27 European Medicines Agency (EMA):. EMEA/CHMP/EWP/192217/2009. Guideline on bioanalytical method validation. February 2012. Zugriff am 17. Februar 2022 unter: https://www.ema.europa.eu/en/bioanalytical-method-validation
    PubMedGoogle Scholar